ipilimumab,nivolumab,cabozantinib
exelixis,bms
['cabozantinib', 'cosmic-313', 'adapt', 'adaptive ']
cosmic-313 presented by dr. choueiri at #esmo22 pfs improved in the iit population. studies on-going like pedigree through will evaluate adaptive cabozantinib dosing. is the increased tox worth the trade off for improved pfs? 
Assistant Attending, MSKCC, Genitourinary Oncology Service

Tweets are my own opinions and do not represent the views or opinions of Memorial Sloan Kettering